Tuesday, 2 February 2016
FDA approves eribulin mesylate for the treatment of unresectable or advanced liposarcoma
On 28 January, 2016 the US Food and Drug Administration (FDA) approved a chemotherapy drug eribulin mesylate (Halaven) for the treatment of unresectable or advanced liposarcoma. This treatment is approved for patients who received prior chemotherapy that contained an anthracycline. Read more here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment